Liver resection: Patients in the intervention group received liver resection and postoperative adjuvant therapy
Locoregional therapy: Patients in the control group received locoregional therapy and systemic therapy
Study summary
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 18-75 years
* Pathological type is HCC, and with PVTT
* No extrahepatic HCC
* Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 and Child-Pugh grade A for the liver resection group
* ECOG performing status of 0-2 and Child-Pugh grade A-B for the locoregional-based group
* Adequate hematologic and organ function
Exclusion Criteria:
* Any history of other malignant tumors or recurrent HCC
* Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency
* Any persistent serious liver resection or locoregional therapy-related complications
* Esophageal and/or gastric variceal bleeding within 6 months
* Inability or refusal to comply with the treatment and monitoring
* Participation in other clinical trials
Primary outcome measure(s)
Overall survival — From date of include in this research until the date of death from any cause, whichever came first, assessed up to 60 months. Overall survival was defined as the period from study inclusion until death from any cause.
Trial sites (1)
Facility
City
Region
Status
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.